Cargando…

People’s willingness to accept overdetection in cancer screening: population survey

Objectives To describe the level of overdetection people would find acceptable in screening for breast, prostate, and bowel cancer and whether acceptability is influenced by the magnitude of the benefit from screening and the cancer specific harms from overdetection. Design Online survey. Women were...

Descripción completa

Detalles Bibliográficos
Autores principales: Van den Bruel, Ann, Jones, Caroline, Yang, Yaling, Oke, Jason, Hewitson, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356995/
https://www.ncbi.nlm.nih.gov/pubmed/25736617
http://dx.doi.org/10.1136/bmj.h980
_version_ 1782361071083847680
author Van den Bruel, Ann
Jones, Caroline
Yang, Yaling
Oke, Jason
Hewitson, Paul
author_facet Van den Bruel, Ann
Jones, Caroline
Yang, Yaling
Oke, Jason
Hewitson, Paul
author_sort Van den Bruel, Ann
collection PubMed
description Objectives To describe the level of overdetection people would find acceptable in screening for breast, prostate, and bowel cancer and whether acceptability is influenced by the magnitude of the benefit from screening and the cancer specific harms from overdetection. Design Online survey. Women were presented with scenarios on breast and bowel cancer, men with scenarios on prostate and bowel cancer. For each particular cancer, we presented epidemiological information and described the treatment and its consequences. Secondly, we presented two different scenarios of benefit: one indicating a 10% reduction in cancer specific mortality and the second indicating a 50% reduction. Setting Online survey of the population in the United Kingdom. Participants Respondents were part of an existing panel of people who volunteer for online research and were invited by email or online marketing. We recruited 1000 respondents, representative for age and sex for the UK population. Main outcome measures Number of cases of overdetection people were willing to accept, ranging from 0-1000 (complete screened population) for each cancer modality and each scenario of benefit. Results There was large variability between respondents in the level of overdetection they would find acceptable, with medians ranging from 113 to 313 cases of overdetection per 1000 people screened. Across all scenarios, 4-7% of respondents indicated they would accept no overdetection at all compared with 7-14% who thought that it would be acceptable for the entire screened population to be overdetected. Acceptability in screening for bowel cancer was significantly lower than for breast and prostate cancer. People aged 50 or over accepted significantly less overdetection, whereas people with higher education levels accepted more; 29% of respondents had heard of overdetection before. Conclusions Acceptability of overdetection in cancer screening is variable. Invitations for screening should include clear information on the likelihood and consequences of overdetection to allow people to make an informed choice.
format Online
Article
Text
id pubmed-4356995
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-43569952015-03-18 People’s willingness to accept overdetection in cancer screening: population survey Van den Bruel, Ann Jones, Caroline Yang, Yaling Oke, Jason Hewitson, Paul BMJ Research Objectives To describe the level of overdetection people would find acceptable in screening for breast, prostate, and bowel cancer and whether acceptability is influenced by the magnitude of the benefit from screening and the cancer specific harms from overdetection. Design Online survey. Women were presented with scenarios on breast and bowel cancer, men with scenarios on prostate and bowel cancer. For each particular cancer, we presented epidemiological information and described the treatment and its consequences. Secondly, we presented two different scenarios of benefit: one indicating a 10% reduction in cancer specific mortality and the second indicating a 50% reduction. Setting Online survey of the population in the United Kingdom. Participants Respondents were part of an existing panel of people who volunteer for online research and were invited by email or online marketing. We recruited 1000 respondents, representative for age and sex for the UK population. Main outcome measures Number of cases of overdetection people were willing to accept, ranging from 0-1000 (complete screened population) for each cancer modality and each scenario of benefit. Results There was large variability between respondents in the level of overdetection they would find acceptable, with medians ranging from 113 to 313 cases of overdetection per 1000 people screened. Across all scenarios, 4-7% of respondents indicated they would accept no overdetection at all compared with 7-14% who thought that it would be acceptable for the entire screened population to be overdetected. Acceptability in screening for bowel cancer was significantly lower than for breast and prostate cancer. People aged 50 or over accepted significantly less overdetection, whereas people with higher education levels accepted more; 29% of respondents had heard of overdetection before. Conclusions Acceptability of overdetection in cancer screening is variable. Invitations for screening should include clear information on the likelihood and consequences of overdetection to allow people to make an informed choice. BMJ Publishing Group Ltd. 2015-03-04 /pmc/articles/PMC4356995/ /pubmed/25736617 http://dx.doi.org/10.1136/bmj.h980 Text en © Van den Bruel et al 2015 http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Research
Van den Bruel, Ann
Jones, Caroline
Yang, Yaling
Oke, Jason
Hewitson, Paul
People’s willingness to accept overdetection in cancer screening: population survey
title People’s willingness to accept overdetection in cancer screening: population survey
title_full People’s willingness to accept overdetection in cancer screening: population survey
title_fullStr People’s willingness to accept overdetection in cancer screening: population survey
title_full_unstemmed People’s willingness to accept overdetection in cancer screening: population survey
title_short People’s willingness to accept overdetection in cancer screening: population survey
title_sort people’s willingness to accept overdetection in cancer screening: population survey
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356995/
https://www.ncbi.nlm.nih.gov/pubmed/25736617
http://dx.doi.org/10.1136/bmj.h980
work_keys_str_mv AT vandenbruelann peopleswillingnesstoacceptoverdetectionincancerscreeningpopulationsurvey
AT jonescaroline peopleswillingnesstoacceptoverdetectionincancerscreeningpopulationsurvey
AT yangyaling peopleswillingnesstoacceptoverdetectionincancerscreeningpopulationsurvey
AT okejason peopleswillingnesstoacceptoverdetectionincancerscreeningpopulationsurvey
AT hewitsonpaul peopleswillingnesstoacceptoverdetectionincancerscreeningpopulationsurvey